Free Trial

ENDRA Life Sciences Q3 2023 Earnings Report

ENDRA Life Sciences logo
$5.91 -0.10 (-1.66%)
As of 01/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ENDRA Life Sciences EPS Results

Actual EPS
-$700.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ENDRA Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ENDRA Life Sciences Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

ENDRA Life Sciences Earnings Headlines

ENDRA Life Sciences Reports Q3 2024 Results and Progress
Trump currency shock imminent
Trump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launched a $1.9 trillion move against the Fed. What comes next could have dramatic consequences.
ENDRA Life Sciences Inc trading halted, news pending
See More ENDRA Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ENDRA Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ENDRA Life Sciences and other key companies, straight to your email.

About ENDRA Life Sciences

ENDRA Life Sciences (NASDAQ:NDRA) develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

View ENDRA Life Sciences Profile

More Earnings Resources from MarketBeat